Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors

Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors

Bromodomain and extra-terminal domain (BET) subfamily is the most studied subfamily of bromodomain-containing proteins (BCPs) family which can modulate acetylation signal transduction and produce diverse physiological functions. Thus, the BET family can be treated as an alternative strategy for targ...

Full description

Bibliographic Details
Main Authors:	Siao Chen, Yi He, Yajiao Geng, Zhi Wang, Lu Han, Weiwei Han
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Molecules
Subjects:	bromodomain and extra-terminal protein 4 (BRD4) inhibitors molecular dynamic simulations conformational changes MM-GBSA calculations
Online Access:	https://www.mdpi.com/1420-3049/27/1/118

Similar Items

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
by: Archit Trivedi, et al.
Published: (2020-03-01)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
by: Kenneth K. W. To, et al.
Published: (2023-03-01)

Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization
by: Yongle Wang, et al.
Published: (2024-12-01)

Bromodomain Proteins in HIV Infection
by: Melanie Ott, et al.
Published: (2013-06-01)

Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
by: Yuting Meng, et al.
Published: (2021-04-01)

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
by: Yanli Sun, et al.
Published: (2021-01-01)

The current status and future trends of BET research in oncology
by: Siying Yu, et al.
Published: (2024-09-01)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
by: Noemi Martella, et al.
Published: (2023-03-01)

Bromodomain Containing Protein 4 (BRD4) Regulates Expression of its Interacting Coactivators in the Innate Response to Respiratory Syncytial Virus
by: Xiaofang Xu, et al.
Published: (2021-10-01)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
by: Jiacheng Lai, et al.
Published: (2021-09-01)

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
by: Adam P. Cribbs, et al.
Published: (2021-02-01)

Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma
by: Dan Zou, et al.
Published: (2024-11-01)

Bromodomain Protein Inhibition Protects β-Cells from Cytokine-Induced Death and Dysfunction via Antagonism of NF-κB Pathway
by: Vinny Negi, et al.
Published: (2024-06-01)

Epigenetic Reader Bromodomain Containing Protein 2 Facilitates Pathological Cardiac Hypertrophy via Regulating the Expression of Citrate Cycle Genes
by: Zhirong Lin, et al.
Published: (2022-05-01)

Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma
by: Qiwei Yang, et al.
Published: (2024-08-01)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
by: Weiping Li, et al.
Published: (2019-07-01)

N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
by: Joshua A. Nord, et al.
Published: (2022-09-01)

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease
by: Katiri J. Snyder, et al.
Published: (2021-10-01)

Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
by: Zhimin Zhang, et al.
Published: (2019-01-01)

Hydrophobic Waters in Bromodomains
by: Serena G. Piticchio, et al.
Published: (2019-08-01)

Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
by: Alfonso Urbanucci, et al.
Published: (2017-06-01)

Bromodomain inhibitors and cancer therapy: From structures to applications
by: Montserrat Pérez-Salvia, et al.
Published: (2017-05-01)

Mitochondrial fission promotes self-renewal and tumorigenic potential in prostate cancer
by: Gianluca Civenni, et al.
Published: (2019-09-01)

BET Bromodomain Degradation Disrupts Function but Not 3D Formation of RNA Pol2 Clusters
by: Diana H. Chin, et al.
Published: (2023-01-01)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
by: Martin V. Nguyen, et al.
Published: (2020-02-01)

Two bromodomain proteins functionally interact to recapitulate an essential BRDT-like function in Drosophila spermatocytes
by: Shuhei Kimura, et al.
Published: (2015-01-01)

Targeting mechanotransduction at the transcriptional level: YAP and BRD4 are novel therapeutic targets for the reversal of liver fibrosis
by: Altynbek Zhubanchaliyev, et al.
Published: (2016-12-01)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
by: Xiyao Shi, et al.
Published: (2022-09-01)

Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer
by: Krishan Kumar, et al.
Published: (2023-05-01)

SAR by Space: Enriching Hit Sets from the Chemical Space
by: Franca-Maria Klingler, et al.
Published: (2019-08-01)

Clinical Diagnosis and Treatment of Primary Lung NUT Midline Carcinoma
by: HE Xinyue, et al.
Published: (2019-11-01)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
by: Dayu Wu, et al.
Published: (2022-08-01)

The Functions of BET Proteins in Gene Transcription of Biology and Diseases
by: Ka Lung Cheung, et al.
Published: (2021-09-01)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
by: Noah R. Flynn, et al.
Published: (2021-06-01)

The Role of Bromodomain Testis-Specific Factor, BRDT, in Cancer: A Biomarker and A Possible Therapeutic Target
by: Ekaterina Flin, et al.
Published: (2017-05-01)

BRD4: An emerging prospective therapeutic target in glioma
by: Hua Yang, et al.
Published: (2021-06-01)

Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
by: Gerhard Hamilton, et al.
Published: (2023-10-01)

Are Terminal Alkynes Necessary for MAO-A/MAO-B Inhibition? A New Scaffold Is Revealed
by: Panagiou Mavroeidi, et al.
Published: (2024-05-01)

The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
by: Chiara Tarantelli, et al.
Published: (2021-12-01)

Development of a Novel Positron Emission Tomography (PET) Radiotracer Targeting Bromodomain and Extra-Terminal Domain (BET) Family Proteins
by: Ping Bai, et al.
Published: (2020-08-01)